DDInter1917 DDInter1435
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Vandetanib {u} (Compound) treats {v} (Disease) thyroid cancer
Vandetanib {u} (Compound) binds {v} (Gene) FMO1
Vandetanib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Vandetanib {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Vandetanib (Compound) resembles Erlotinib (Compound)
Vandetanib (Compound) treats thyroid cancer (Disease)
Vandetanib (Compound) binds FMO1 (Gene)
Vandetanib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Vandetanib (Compound) causes Blood creatinine increased (Side Effect)
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Vandetanib may lead to a major life threatening interaction when taken with Lefamulin